Research from the 2025 ASCO Annual Meeting showed encouraging survival outcomes with second-line lurbinectedin for extensive-stage non-small cell lung cancer. The post Real-World Data Affirms Second-Line Therapy’s Efficacy in ES-SCLC […]
The post Real-World Data Affirms Second-Line Therapy’s Efficacy in ES-SCLC first appeared on Blackandmed .
